Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

Rupp, Richard; J. Luckasen, Gary; L. Kirstein, Judith; E. Osorio, Jorge; D. Santangelo, Joseph; G. Raanan, Marsha; Kathryn Smith, Mary; Wallace, Derek; S. Gordon, Gilad; T. Stinchcomb, Dan

doi:10.1016/j.vaccine.2015.09.008

Public

Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

Published in Vaccine • Sep 15, 2015

Authors:

Richard Rupp

Gary J. Luckasen

Judith L. Kirstein

Abstract

INTRODUCTION: A safe, effective dengue vaccine that can simultaneously induce immunity to all four dengue virus serotypes (DENV-1-4) is a public health priority. A chimeric tetravalent dengue vaccine (TDV) based on an attenuated DENV-2 serotype backbone was evaluated in healthy, flavivirus-seronegat...

Subject

Immunogenicity

Dengue vaccine

Dengue fever

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!